



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/534088/2024

## European Medicines Agency decision P/0396/2024

of 6 December 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral for gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012), (EMA-003592-PIP01-24) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0396/2024

of 6 December 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral for gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012), (EMA-003592-PIP01-24) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Precigen, Inc. on 23 February 2024 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012), the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012), the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to Precigen, Inc., 20358 Seneca Meadows Parkway, MD 20876 – Germantown, USA.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/328498/2024  
Amsterdam, 18 October 2024

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-003592-PIP01-24

### Scope of the application

#### Active substance(s):

Gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012)

#### Invented name and authorisation status:

See Annex II

#### Condition(s):

Treatment of respiratory papillomatosis

#### Pharmaceutical form(s):

Suspension for injection

#### Route(s) of administration:

Subcutaneous use

#### Name/corporate name of the PIP applicant:

Precigen, Inc.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Precigen, Inc. submitted for agreement to the European Medicines Agency on 23 February 2024 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 2 April 2024.

Supplementary information was provided by the applicant on 1 July 2024. The applicant proposed modifications to the paediatric investigation plan.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

## 1. Waiver

Not applicable

## 2. Paediatric investigation plan

### 2.1. Condition:

Treatment of respiratory papillomatosis

#### 2.1.1. Indication(s) targeted by the PIP

Treatment of recurrent respiratory papillomatosis

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

#### 2.1.3. Pharmaceutical form(s)

Suspension for injection

#### 2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	<b>Study 1 (PRGN-2012-302)</b> Randomised controlled, double-blind study of PRGN-2012 to evaluate efficacy and duration of response in children from birth to less than 18 years of age with recurrent respiratory papillomatosis.
Modelling and simulation analyses	Not applicable
Other studies	Not applicable
Extrapolation plan	Not applicable

## 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

## **Annex II**

### **Information about the authorised medicinal product**



***Information provided by the applicant:***

**The product is not authorised anywhere in the European Community.**